Physician profile

Robert S Trainor

Vascular Neurology · New Orleans, LA

NPI 1902245673

$823.57

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$300.89

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Alexion Pharmaceuticals, INC. $274.57 2019
Abbvie INC. $126.57 2021-2024 Ubrelvy
Astrazeneca Pharmaceuticals LP $115.01 2023
Pfizer INC. $82.05 2023-2024
Biohaven Pharmaceutical Holding Company LTD. $55.91 2022
Ucb, INC. $47.53 2024 Briviact
Amgen INC. $41.50 2022
Biohaven Pharmaceuticals, INC. $39.07 2021
E.R. Squibb & Sons, L.L.C. $21.31 2020
Portola Pharmaceuticals, LLC $20.05 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert S Trainor

$823.57

in general payments reported 2019-2025

Years
2019-2024
Top company
Alexion Pharmaceuticals, INC.

https://glasscript.com/doctor/6340213/robert-s-trainor

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.